Integra

Integra LifeSciences Completes the Acquisition of Acclarent, Inc.

Retrieved on: 
Monday, April 1, 2024
Nose, Ear, Integra, Acquisition, Neurosurgery, ENT

PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical interventions.

Key Points: 
  • PRINCETON, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Acclarent, Inc. , a pioneer in ear, nose and throat (ENT) surgical interventions.
  • The addition of Acclarent's innovative product portfolio expands the breadth of Integra’s market-leading brands and provides immediate scale and accretive growth via a dedicated sales channel.
  • The acquisition adds $1 billion to the total addressable market of the Company’s offerings, while providing unique market opportunities for access to the attractive ENT device segment.
  • A webcast replay of the conference call will be posted on the investor section of the Company’s website following the call.

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Longevity, Rheumatoid arthritis, Prevalence, Partnership, Patient, AAOS, Elbow, Polyethylene, American Academy, Acquisition, Motion, Quality of life, Injury, Integra, Shoulder, Metal, Partial, Key, Pain, Osteoarthritis, USD, Collection, Plumbing

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.

Global Elbow Replacement Market to surpass $200.4 million by 2031, at a CAGR of 4.2%, says Coherent Market Insights

Retrieved on: 
Monday, April 8, 2024
Longevity, Rheumatoid arthritis, Prevalence, Partnership, Patient, AAOS, Elbow, Polyethylene, American Academy, Acquisition, Motion, Quality of life, Injury, Integra, Shoulder, Metal, Partial, Key, Pain, Osteoarthritis, USD, Collection, Plumbing

Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.

Key Points: 
  • Elbow replacement surgery is a medical procedure that involves replacing a damaged or diseased elbow joint with an artificial implant.
  • As per the market research report, the elbow replacement market was valued at USD 144.2 million in 2023, with a projected CAGR of 4.2% during the forecast period 2024-2031.
  • Buy this Complete Business Research Report: https://www.coherentmarketinsights.com/insight/buy-now/6663
    In terms of type, the elbow replacement market is segmented into partial elbow replacement and total elbow replacement.
  • Partial elbow replacement is expected to dominate the market, owing to its less invasive nature and shorter recovery time compared to total elbow replacement.

Turkish Broker Integra Licenses CyberCube Software to Bolster Cyber Growth

Retrieved on: 
Monday, March 25, 2024
Software, Insurance, Networks, Data Analytics, Data Management, Professional Services, Technology, Security, Risk, Integra, Ecosystem

Integra Insurance and Reinsurance Broking Services is to become the first Turkish broker to roll out CyberCube’s Broking Manager , the cyber risk analytics platform for insurance intermediaries.

Key Points: 
  • Integra Insurance and Reinsurance Broking Services is to become the first Turkish broker to roll out CyberCube’s Broking Manager , the cyber risk analytics platform for insurance intermediaries.
  • Integra holds a prominent position in the Turkish market as the leading cyber insurance broker.
  • It will license Broking Manager to bolster its growth plans for cyber and gain a competitive edge in this market.
  • Emma Drouineau, Sales Manager at CyberCube, said: “Integra will be the first Turkish broker to utilize CyberCube’s Broking Manager platform to better support clients with their cyber insurance needs.

Integra LifeSciences Launches MicroMatrix® Flex to Provide Convenient Access to Hard-to-Reach Areas in Complex Cases

Retrieved on: 
Monday, March 11, 2024
Flex, Regenerative medicine, Integra, Global marketing, Surgeon, UBM, Development, Research, Management

PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas.

Key Points: 
  • PRINCETON, N.J., March 11, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART), today announced MicroMatrix® Flex is now available commercially in the U.S. MicroMatrix Flex is a dual-syringe system enabling the convenient mixing and precise delivery of MicroMatrix® paste to provide convenient access to hard-to-reach spaces and to help prepare an even wound surface in challenging wound areas.
  • “MicroMatrix Flex has allowed me to expand how I use UBM technology in complex wound reconstruction procedures,” said Dr. Aaron Moore, acute care surgeon, Mercy Health - St. Vincent Medical Center.
  • During this period, UBM has been published in more than 200 pre-clinical and clinical publications.
  • “We’re excited to be adding MicroMatrix Flex to our market-leading portfolio of dermal matrices,” commented Steve Powick, senior vice president, Global Marketing, Tissue Technologies Product Division.

Integra LifeSciences Announces Leadership Transition Plan

Retrieved on: 
Wednesday, February 28, 2024
Integra, Growth, Acceleration, Heidrick & Struggles, Trust, Workforce, Management

PRINCETON, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (“Integra” or “the Company”) (NASDAQ: IART), a leading global medical technology company, today announced that Jan De Witte has informed the Board of Directors (the “Board”) of his intention to retire from his position as president and chief executive officer of Integra following the appointment of a successor, which the Company expects to occur by the end of 2024. The Company also announced that Stuart Essig, Integra’s chairman, has been appointed to the role of executive chairman, effective immediately.

Key Points: 
  • “We are grateful to Jan for his leadership and commitment to Integra and the role he has played in advancing our portfolio and building upon our legacy of innovation,” said Stuart Essig, chairman of the Board.
  • “Jan’s personal decision to retire from Integra and return to Europe follows a leadership tenure marked by significant contributions to the company, including the evolution of our strategy and an expansion of core capabilities.
  • Mr. De Witte said, “I am incredibly proud of everything we have accomplished together here at Integra.
  • Mr. De Witte will address the leadership transition during Integra’s fourth quarter and full-year 2023 financial results conference call, which is scheduled for later today at 8:30 a.m.

2024 Canadian Car of the Year winners announced by Automobile Journalists Association of Canada

Retrieved on: 
Thursday, February 15, 2024
Toyota, International Auto Show, Genesis G80, Integra, SUV, Toyota Prius, Acura, Sale, Type S, Hyundai Ioniq 5, Accord, Toyota Highlander, Genesis, Utility vehicle, G80, Kia, Hyundai, Automotive industry

TORONTO, Feb. 15, 2024 /CNW/ - The four winners of the 2024 Canadian Car of the Year Awards (CCOTY), presented by the Automobile Journalists Association of Canada (AJAC), were announced today during the opening ceremonies of the Canadian International Auto Show.

Key Points: 
  • TORONTO, Feb. 15, 2024 /CNW/ - The four winners of the 2024 Canadian Car of the Year Awards (CCOTY), presented by the Automobile Journalists Association of Canada (AJAC), were announced today during the opening ceremonies of the Canadian International Auto Show.
  • The Toyota Prius is the 2024 Canadian Car of the Year.
  • The 2024 Canadian Utility Vehicle of the Year is the Toyota Grand Highlander.
  • The Genesis Electrified G80 takes home the award as the 2024 Canadian Electric Car of the Year.

INVESTIGATION ALERT: Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term Investors to Contact the Firm

Retrieved on: 
Wednesday, February 14, 2024
Complaint, Acquisition, Integra, Boston, FDA, Lipopolysaccharide, Management control system, Pharmaceutical industry

PHILADELPHIA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company’s long-term investors.

Key Points: 
  • PHILADELPHIA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it has commenced an investigation into Integra LifeSciences Holdings Corp. (NASDAQ: IART) (“Integra”) on behalf of the company’s long-term investors.
  • After receiving the 2018 Form 483, Integra issued a series of responses purporting to address the problems identified by the FDA.
  • Integra shareholders who purchased or acquired their shares prior to April 26, 2023 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation.

Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024

Retrieved on: 
Wednesday, February 7, 2024
Integra

PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open.

Key Points: 
  • PRINCETON, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024, prior to the market open.
  • In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m.
  • For those planning to participate on the call, register here to receive dial-in details and an individual pin.
  • A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

Cylera and Integra e-Quip Forge Alliance to Enhance Healthcare Cyber Defence and IoT Asset Management

Retrieved on: 
Tuesday, January 23, 2024
Classification, Patient, HPH, Internet, Health care, CMMS, Partnership, Intelligence, Trust, Integra, Public, IoMT, Safety, Internet of things, Pharmaceutical industry

Users of e-Quip with Cylera can now gain automated discovery, classification, and inventory management for all their connected IoMT assets.

Key Points: 
  • Users of e-Quip with Cylera can now gain automated discovery, classification, and inventory management for all their connected IoMT assets.
  • Together, we're transforming the approach to IoT security in the field of healthcare, making proactive defence possible."
  • Our collaboration with Cylera underscores our dedication to supplying top-tier solutions for device management, vendor monitoring, and preventative maintenance.
  • By incorporating IoT security from Cylera into our services, we are empowering our customers to reach unprecedented heights in operational performance and protection."